115 results
424B5
MRSN
Mersana Therapeutics Inc
9 May 24
Prospectus supplement for primary offering
5:06pm
with this offering by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts.
EXPERTS
Ernst & Young LLP, independent registered public … price of the securities above independent market levels. Any such underwriters are not required to engage in these activities and may end any
DEFA14A
MRSN
Mersana Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
6:04am
of the Company’s named executive officers. For 3. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public
8-K
EX-1.1
MRSN
Mersana Therapeutics Inc
28 Feb 24
Entry into a Material Definitive Agreement
4:08pm
) Independent Accountants. Ernst & Young LLP, who have certified certain financial statements of the Company and its subsidiary, is an independent … attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company shall cause its independent accountants to furnish Cowen letters
424B5
puo3go5hn13t s6e0q
28 Feb 24
Prospectus supplement for primary offering
4:07pm
POS AM
32dx6u fd7
28 Feb 24
Prospectus update (post-effective amendment)
4:05pm
POS AM
EX-23.1
xx0xsh7q2
28 Feb 24
Prospectus update (post-effective amendment)
4:05pm
POSASR
x2tfvw8wq7 4oxi0n1o
28 Feb 24
Automatic shelf registration (post-effective amendment)
8:43am
POSASR
EX-23.1
eygs415
28 Feb 24
Automatic shelf registration (post-effective amendment)
8:43am
S-8
dp8wsr tvwoqh3
12 Jan 24
Registration of securities for employees
4:42pm
S-8
EX-23.2
azgu0srg82di78g tr
12 Jan 24
Registration of securities for employees
4:42pm
8-K
aut5b8q4ntf
27 Jul 23
Results of Operations and Financial Condition
7:32am
8-K
EX-99.1
c5rw7t
27 Jul 23
Results of Operations and Financial Condition
7:32am
8-K
gb50cxe
9 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:25pm